Based on the findings, the predictors obtained from the combined testing of NLR, IL-6, and TyG emerge as the most practical and readily accessible indicators for early screening of NAFLD from patients with T2DM. The gene discussed is IL6; the disease is metabolic dysfunction-associated steatotic liver disease.